Phathom Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $413.84 Mil.
During the past 12 months, Phathom Pharmaceuticals's average Total Assets Growth Rate was 244.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 62.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 171.80% per year.
During the past 6 years, Phathom Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 545.00%. The lowest was -11.10%. And the median was 62.10%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Phathom Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals (NAS:PHAT) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Phathom Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Phathom Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Phathom Pharmaceuticals (Phathom Pharmaceuticals) Business Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PHAT has been successfully added to your 